TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025.

Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...

New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in ...

Researchers from the Translation Center for Regenerative Therapies TLC-RT at the Fraunhofer Institute for Silicate Research ...